Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aptamer Group Plc LSE:APTA London Ordinary Share GB00BNRRP542 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 96.00 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
92.00 100.00 96.00 96.00 96.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 66
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 96.00 GBX

Aptamer (APTA) Latest News

More Aptamer News
Aptamer Investors    Aptamer Takeover Rumours

Aptamer (APTA) Discussions and Chat

Aptamer Forums and Chat

Date Time Title Posts
18/6/202212:09☆☆ Aptamer Group - Novel Antibody Mimetics (Optimers) ☆☆23

Add a New Thread

Aptamer (APTA) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Aptamer trades in real-time

Aptamer (APTA) Top Chat Posts

DateSubject
03/7/2022
09:20
Aptamer Daily Update: Aptamer Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker APTA. The last closing price for Aptamer was 96p.
Aptamer Group Plc has a 4 week average price of 96p and a 12 week average price of 96p.
The 1 year high share price is 153p while the 1 year low share price is currently 96p.
There are currently 69,012,594 shares in issue and the average daily traded volume is 1,175 shares. The market capitalisation of Aptamer Group Plc is £66,252,090.24.
24/2/2022
06:52
timbo003: Liberum have issued an initiation note this morning https://www.research-tree.com/companies/uk/health/aptamer-group-plc/APTA/LON Summary: The affinity ligand market is large (~$145bn) and growing at double digits. It is dominated by antibody technology, but they aren’t perfect, falling short of requirements 50% of the time. Aptamer has developed an alternate affinity ligand technology that has proven effective in 70% of projects where antibodies have failed. Aptamer’s fee-for-service model is gaining traction with healthcare partners across a range of applications, and the BD pipeline has grown accordingly. Our DCF model values Aptamer at £185m, or £2.70 per share, 105% upside. We initiate with a BUY.
24/1/2022
10:54
amanitaangelicus: Still holding small amount. No interest in the stock. Will take time. Sell price set from the outset.
17/1/2022
13:51
elpirata: Yes, already contracted with big pharma & should see revenue increases compounding year on year. But its the wrong price for me to buy in at this level, £98m mcap for a company that reported a £2.9m loss on £1.6m revenues for the 15 month period to 30/6/21 is too hot imo. They need £3m pa just to cover staff & director costs. Keeping it on monitor.
Aptamer share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
APTA
Aptamer
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220703 11:40:24